Cover storyFDA’s Proposed DTC Rule would remove the adequate provision option for broadcast drug ads, requiring full risk information in every spot. See what pharma leaders can do now.
Teva acquires BioXcel assets, advancing a late-stage at-home acute agitation treatment with complex device-drug combination regulatory implications.
Sudeep Pharma secures FDA approval for its Nandesari, Gujarat facility, with US commercial supplies targeted for H2 FY27.
Jubilant Biosys appoints Dr. SK Dhakshinamoorthy as Senior VP of Strategy and Value Creation, signalling a formalised capability expansion agenda.
FDA has renewed the Peripheral and CNS Drugs Advisory Committee charter, resetting a two-year cycle governing neurological drug advisory reviews.
Latest edition
Interview
Interview
Interview
Podcast
SPONSORED
SPONSORED
SPONSORED
20261021202001.png&w=1920&q=75&dpl=dpl_7CEvJjuEepPZ7Lf4AhsGNGozWe17)
Oct 28
Nov 18
Nov 28From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
